Capital Raising Mistakes Early-Stage Life Sciences Founders Make Before Series A

Funding headlines make early-stage biotech look easy. Fierce Biotech's 2026 fundraising tracker lists combined seed and Series A rounds of $106 million for Tortugas Neuroscience and $175 million for Korsana Biosciences. A MassBio report covered by BioPharma Dive shows the other side. Massachusetts drugmakers raised almost $3.5 billion in venture funding in the first half of 2026, up 25 percent on the year before. Yet the average seed round fell to $4.65 million while the mean Series A climbed to nearly $80 million. That is roughly a seventeen-fold jump between rounds, and MassBio named the earliest companies with the riskiest science as its biggest concern. Founders are expected to cross that gap on a seed-sized budget. Every mistake below makes the crossing harder.

1. Starting the Raise When Runway Is Already Short

Founders often open investor conversations with six months of cash, because the team is busy and the data is not quite ready. A seed or bridge process takes months of meetings, diligence and legal work, and investors read short runway as weakness. In our experience, you should start preparing with at least nine to twelve months of cash left, and treat the first three months as groundwork rather than outreach. Starting early also lets you walk away from a poor term sheet, which is the only real leverage a founder has.

2. Raising Against a Milestone Series A Investors Do Not Value

A seed round should buy a specific milestone that changes the risk profile: an in vivo proof of concept, a development candidate, IND-enabling studies or an early clinical read-out. Too many founders raise to "advance the platform," which funds activity without reducing risk. Before you set a target, ask Series A investors in your space what evidence would make them lead. Then work backwards from their answer to the cash you need. If three investors give you three different answers, that is a finding too, and it is better to hear it before you raise than after.

3. Sizing the Round to the Burn Rate, Not the Milestone

Some teams multiply monthly burn by twelve, call it a round and move on. If the milestone takes eighteen months, the money runs out mid-experiment and you are fundraising again with half-finished data. Build a bottom-up budget for the milestone instead. Add a buffer for slippage in manufacturing and CRO timelines, and size the round to that figure. A slightly larger raise at a fair valuation is often cheaper than a rescue bridge later.

4. Pitching Investors Who Do Not Fit

Biotech is a specialist market. A generalist fund that has never underwritten preclinical risk will cost you months and some credibility. Build your target list by thesis, check size and stage, and look at who has led recent rounds in your modality. The MassBio data suggests early-stage investors are becoming more selective, so warm introductions to the right fifteen funds will do more than cold emails to a hundred. Track every conversation, including why a fund passed. Those reasons are the cheapest market research you will get.

5. Choosing the Instrument Without Thinking About Series A

Convertible notes are quick and inexpensive to close, which is why bridges often use them. The risk is that terms written in a hurry become problems at Series A.

Caps, Discounts and Maturity

A valuation cap that looks generous today can still convert at a surprising price once notes, accrued interest and a new priced round stack up. A maturity date of one to two years can also force a hard conversation if your milestone slips. Model the conversion at three plausible Series A valuations before you sign, so you see founder dilution on the page and not for the first time in a term sheet.

Who Holds the Notes

A note with many small holders can slow a Series A close, because amendments may need broad consent. Fewer, more engaged investors are usually easier to manage when the next lead wants changes.

6. Treating Legal Housekeeping as an Afterthought

Series A investors diligence the basics: clean IP assignment, university license terms, board minutes and securities filings. A company selling securities under Regulation D must file a Form D within 15 days after the first sale, which the SEC's own guidance defines as the date the first investor is irrevocably committed. It is a short filing, but a missed deadline makes a Series A lawyer ask harder questions about everything else. Put it on the closing checklist from day one.

A Mistake That Shows Up After the Close

7. Treating a Bridge as Extra Time Instead of a Plan

A bridge feels like relief, and it can be. But in bridge work like our $10M convertible note engagement, the same lesson holds: the money only buys time if the milestones, reporting cadence and Series A timeline are agreed upfront. Without them, existing investors disagree about what success looks like, and the next lead meets a company that seems to have drifted. Write a one-page plan for the bridge period, send monthly updates to note holders, and decide at the outset what happens if the milestone is missed.

What a Planned Pre-Series A Raise Looks Like

A well-run process has a rhythm. In the first quarter, you define the milestone, build the budget and test the story with two or three friendly investors. In the second, you prepare the data room, settle terms and approach target funds in a tight window, so interest builds together instead of trickling in. The third quarter is for diligence and close, with legal housekeeping running in parallel. Afterwards, you update investors monthly so the Series A conversation starts warm. The approach in our seed close case study followed this pattern, and it is the one we apply to every early-stage client.

When Fundraising Consulting Services Make Sense

Not every founder needs outside help. If you have an experienced CFO, strong investor relationships and spare time, you may run a clean process yourself. Fundraising consulting services earn their fee when the team is science-heavy and finance-light, when the raise competes with trial or CMC work for attention, or when a bridge needs its terms modelled before you commit. Look for an adviser who has closed rounds at your stage, will model dilution openly and can explain exactly how they are paid.

Illumination Strategy works with early-stage life sciences founders on this, from milestone definition and round sizing to investor targeting and structuring. If that sounds like where you are, start with a conversation about your milestone and runway, not your deck.

Putting It Together

The seven mistakes share one root: treating capital raising as an event instead of a plan. Start with enough runway, tie the round to a milestone investors value, size it from a real budget, target the right funds, model your instrument, tidy your legal file and plan the bridge before you need it. None of that guarantees a Series A in a market where the average round is so far from the average seed. It does make sure that when the right investor looks, there is nothing avoidable in the way.

What is capital raising for an early-stage life sciences company?

Capital raising is the process of securing funds from investors in exchange for equity or convertible instruments. For early-stage life sciences companies, it usually means pre-seed, seed and bridge financing that funds preclinical work and sets up a Series A. It involves milestone planning, investor targeting, deal structuring and legal compliance, not just pitching.

How much should a life sciences startup raise before Series A?

Raise what the next value-creating milestone costs, plus a buffer for delays. That figure comes from a bottom-up budget covering studies, manufacturing, staff and legal costs, not from a round number. Averages vary widely by region and modality, so benchmark against recent comparable rounds, but let your milestone and timeline set the size.

When should founders start raising before Series A?

Begin preparing nine to twelve months before cash runs out. Raises often take three to six months from first meeting to close, and the preparation phase before outreach adds more. Starting early gives you room to negotiate, to survive a slow quarter in the market and to avoid accepting a rescue bridge on poor terms.

Is a convertible note better than a priced seed round?

Neither is better in every case. Notes close faster and cost less in legal fees, which suits bridges and short timelines. Priced rounds set a valuation and cleaner cap table terms but take longer. The right choice depends on investor appetite, how soon Series A is expected and how much dilution each structure creates at conversion.

What do Series A investors expect to see from a seed-stage company?

They expect a clear de-risking milestone achieved or close, credible data, a defensible IP position and a team able to run the next stage. They also look for clean legal records and a cap table without unusual obligations. Evidence of disciplined spending against a plan tends to count as much as the headline result.

What do fundraising consulting services actually do?

A good fundraising consultant helps define the milestone, size the round, model dilution, build the investor target list and prepare materials and the data room. They may coach pitches and manage the process timeline. Their value is structure and experience, as they do not replace the founder in investor meetings or guarantee a result.

How are fundraising consultants usually paid?

Common models include monthly retainers, fixed project fees and success fees tied to capital raised. Success fees linked to investor introductions can raise securities regulation questions, so ask any adviser how their compensation is structured and whether it complies with applicable rules. Have your lawyer review the engagement terms before signing.

What is a bridge round and when is it a mistake?

A bridge is a smaller financing that extends runway between major rounds, often through convertible notes. It becomes a mistake when it has no defined milestone, when terms are agreed in a rush or when it only delays a failing plan. Used deliberately, with a clear Series A timeline, it can protect momentum.

Do early-stage companies have to file anything with the SEC after raising?

Often yes. Companies that sell securities under Regulation D, including most seed and bridge rounds, must file a Form D within 15 days after the first sale, plus any state notice filings. There is no SEC fee, but late filing creates diligence friction. Ask your securities counsel to calendar the deadline at signing.